BMY Stock Analysis: Buy, Sell, or Hold?
BMY - Bristol-Myers Squibb Co.
$59.31
-2.42 (-3.92%)
▼
5d:
-0.2%
30d:
-4.85%
90d:
+9.96%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: Apr 30, 2026
27d
Smart Money Accumulation
BMY is down 4.5% this week, but smart money is accumulating calls. Top strike: $57.5 2026-06-18 with 10,738 OI. Call ratio: 63% View Scanner →
Strength: 3.5/10
Get Alerted When BMY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BMY shows positive signals but monitor for confirmation. Market pricing in 2.4% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: BMY shows positive signals but monitor for confirmation. Market pricing in 2.4% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$60.45
Based on 0.9% avg growth
INTRINSIC VALUE TODAY
$37.53
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMY is currently trading at $59.31, which is considered fair relative to its 30-day fair value range of $58.58 to $61.49. The stock's valuation (Forward PE: 10.1) is in line with its historical norms (9.4). At these levels, the market is pricing in 2.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BMY is in a strong uptrend. Immediate support is located at $56.45, while resistance sits at $62.23. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: BMY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BMY is in a strong uptrend. Immediate support is located at $56.45, while resistance sits at $62.23. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: BMY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$58.58 -
$61.49
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- NEUTRAL: Near Wall St target ($62.72)
- NEUTRAL: Market pricing in 2.4% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$58.58 -
$61.49
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$56.45
Resistance Level
$62.23
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.05
Wall Street Target
$62.72
(+1.6%)
Revenue Growth (YoY)
1.3%
Earnings Growth (YoY)
1392.1%
Profit Margin
14.6%
Valuation Premium vs History
+2.4% premium
PE vs Historical
10.1 vs 9.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.4%
(market-implied from PE analysis)
1-Year Target
$63.21
(+2%)
2-Year Target
$64.73
(+5%)
3-Year Target
$66.28
(+7%)
3-Yr Target (if PE normalizes)
(PE: 10→9)
PE COMPRESSION
$61.98
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: -2.1%)
$128.77
(+109%)
Base:
(SPY PE: 10.1, Growth: -2.1%)
$57.92
(-6%)
Bear:
(PE: 8.5, Growth: -2.1%)
$49.23
(-20%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (17x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 16.61 | Current EPS (TTM): $3.46
Bull Case
$112.21
(+97%)
Analyst growth 77.5%, PE expands to 18.3
Base Case
$102.01
(+79%)
Market implied 77.5%, PE stable at 16.6
Bear Case
$39.09
(-31%)
Severe decline -20.0%, PE contracts to 14.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: April 02, 2026 12:37 PM ET
Data refreshes hourly during market hours. Next update: 1:37 PM
Data refreshes hourly during market hours. Next update: 1:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMY showing a specific setup today?
Insider Activity (6 Months)
5
Buys
4
Sells
+
Net
NEUTRAL
Recent Transactions
Ro Khanna
BUY
2026-02-05
Ro Khanna
SELL
2026-01-29
Ro Khanna
BUY
2026-01-23
Featured in Portfolios
BMY is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 58 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 54 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$249 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$351 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$206 | 57 HOLD |
Advanced BMY Option Strategies
Professional options setups generated by AI based on today's BMY price and gamma walls.
